A Phase I Dose Escalating Study Evaluating the Pharmacodynamic Profile and Safety of BN83495 in Patients With Prostate Cancer With Evidence of Disease Progression While on Androgen Ablative Therapy.
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2011
At a glance
- Drugs Irosustat (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 28 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Oct 2010 Planned end date changed from 1 Aug 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.